> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rare Disease Status Given to Duchenne Therapy
- URL: https://www.fdaweb.com/rare-disease-status-given-to-duchenne-therapy/
- Published: 2024-08-15T12:00:00.000Z
- Updated: 2026-09-14T14:38:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157585

FDA has granted Wave Life Sciences a rare pediatric disease designation for WVE-N531 and its use in treating boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping. The therapy is currently being evaluated in the registrational FORWARD-53 clinical trial, and the company says it expects release data, including dystrophin protein expression from muscle biopsies after 24 weeks of treatment, in the third quarter of this year.

WVE-N531 is described as an exon-skipping oligonucleotide designed to induce the production of endogenous, functional dystrophin protein. Previously released study data showed that the therapy “achieved industry-leading mean exon skipping levels of 53%,” the company says.